Watson To License Takeda's Actos In Patent Deal

Law360, New York (March 10, 2010, 2:46 PM EST) -- Takeda Chemical Industrials Ltd. has agreed to license diabetes medication Actos to rival Watson Pharmaceuticals Inc. and drop a long-running patent infringement case, the generics maker announced Wednesday.

Under the terms of the deal, which resolves litigation in the U.S. District Court for the Southern District of New York, Watson will gain a nonexclusive royalty-free license to Takeda's U.S. patents covering Actos, the brand-name for pioglitazone hydrochloride, Watson said in a statement.

Actos is an oral medication used to reduce insulin resistance in type 2 diabetics....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.